Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Interview with Roger Tung, CEO discussing the company's deuterium chemistry platform for creating new drugs which have superior properties—including enhanced clinical safety, tolerability or efficacy—based on compounds that have established pharmacological activity. The company's current pipeline has 3 drugs which have "blockbuster potential" for treating, alopecia areata, schizophrenia, and Alzheimers agitation.
. . .
This content is available to members only.
If you are an existing member, please LOGIN
Note a member? Sign up for a FREE account ($89 per month value), and get immediate access. Free offer expires March 15, 2019.
Register New Account
Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2